#Senior Notes #Boston Scientific #AMS Europe

Boston Scientific's Significant Financial Move

On February 21, 2025, Boston Scientific Corporation, a leading global medical technology company, made headlines by announcing a substantial public offering of €1.5 billion in senior notes through its wholly-owned finance subsidiary, American Medical Systems Europe B.V. This move is set to further strengthen the company’s financial foundation as it continues its mission to transform lives through innovative medical technologies.

Details of the Offering

Boston Scientific has priced €850 million of 3.000% notes maturing in 2031 and €650 million of 3.250% notes maturing in 2034. The offering will be fully guaranteed by Boston Scientific, providing additional security for investors. The offering will close on February 26, 2025, pending the satisfaction of customary closing conditions. This initiative is marked under a registration statement previously filed with the U.S. Securities and Exchange Commission.

Purpose of the Funds

The funds generated through this offering will be primarily allocated to repaying AMS Europe’s outstanding 0.750% senior notes, due March 8, 2025. In addition, the proceeds will cover accrued and unpaid interest related to those notes. Any remaining funds will assist in general corporate purposes, which may include short-term investments, reducing short-term debt, and sustaining working capital for potential future acquisitions.

Boston Scientific has a long-standing commitment to innovation in the medical field, focusing on improving health care quality worldwide. This ambitious fundraising effort will help the company maintain its competitive edge and continue providing high-performance solutions that cater to complex medical needs.

Market Impact and Future Outlook

Joe Khan, Boston Scientific's Chief Financial Officer, said that this offering reflects the company’s proactive financial management strategy.